NASDAQ: RPIDRapid Micro Biosystems Inc Stock
$0.89+0.03 (+3.49%)
Updated Apr 19, 2024
RPID Price
$0.89
Fair Value Price
$1.58
Market Cap
$37.82M
52 Week Low
$0.74
52 Week High
$1.19
P/E
-0.73x
P/B
0.32x
P/S
1.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.52M
Earnings
-$52.47M
Gross Margin
-24.4%
Operating Margin
-251.55%
Profit Margin
-233%
Debt to Equity
0.22
Operating Cash Flow
-$45M
Beta
1.14
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RPID Overview
Rapid Micro Biosystems Incorporated offers automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship platform, Growth Direct, automates manual microbial quality control (MQC), testing workflows used in pharmaceutical manufacturing operations. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. Rapid Micro Biosystems was incorporated in 2006 and is headquartered in Lowell, MA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RPID scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RPID ($0.89) is undervalued by 43.53% relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RPID ($0.89) is significantly undervalued by 43.53% relative to our estimate of its Fair Value price of $1.58 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
RPID is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RPID due diligence checks available for Premium users.
Be the first to know about important RPID news, forecast changes, insider trades & much more!
RPID News
Valuation
RPID fair value
Fair Value of RPID stock based on Discounted Cash Flow (DCF)
Price
$0.89
Fair Value
$1.58
Undervalued by
43.53%
RPID ($0.89) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RPID ($0.89) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RPID is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RPID price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.73x
Industry
28.69x
Market
40.51x
RPID price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.32x
Industry
3.63x
RPID is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RPID's financial health
Profit margin
Revenue
$6.3M
Net Income
-$11.2M
Profit Margin
-176.3%
RPID's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RPID's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$143.5M
Liabilities
$25.5M
Debt to equity
0.22
RPID's short-term assets ($120.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RPID's short-term assets ($120.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RPID's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.5M
Investing
$10.0M
Financing
-$12.0k
RPID's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RPID vs Medical Device Stocks
Rapid Micro Biosystems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.